Berotralstat provides sustained reduction in HAE attack rates and improvement in quality of life in adolescent patients: A subgroup analysis from APeX-S

被引：0
|
作者：
Reshef, A. [1 ]
Wedner, H. J. [2 ]
Johnston, D. T. [3 ]
Tomita, D. [3 ]
Desai, B. [3 ]
Smith, A. M. [4 ]
Stobiecki, M. [5 ]
Bernstein, J. [6 ]
机构：
[1] Barzilai Govt Hosp, Ashqelon, Israel
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] BioCryst Pharmaceut Inc, Durham, NC USA
[4] Allergy Associates Utah, Murray, KY USA
[5] Uniwersytet Jagiellonski, Coll Med, Krakow, Poland
[6] Univ Cincinnati, Coll Med, Cincinnati, OH USA
来源：
ALLERGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
001108
引用
收藏
页数：2
相关论文
共 17 条
  • [1] Berotralstat demonstrates consistentlyllow HAE attack rates during COVID-19: subgroup analysis from the apeX-S trial
    Ford, Burnette A.
    Panovska, V. G.
    Desai, B.
    Aggarwal, K.
    Murray, S. C.
    Soteres, D. F.
    [J]. ALLERGY, 2021, 76 : 213 - 214
  • [2] BEROTRALSTAT REDUCED ATTACK RATES COMPARED TO BASELINE IN PATIENTS WITH HEREDITARY ANGIOEDEMA IN APEX-S
    Wedner, H.
    Johnston, D.
    Tomita, D.
    Noble, L.
    Zafra, H.
    Craig, T.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S32 - S32
  • [3] SUSTAINED REDUCTION IN HEREDITARY ANGIOEDEMA ATTACK RATES FOLLOWING SWITCH TO BEROTRALSTAT: SUBGROUP ANALYSIS FROM APEX-2
    Kinaciyan, T.
    Sheridan, W.
    Desai, B.
    Tomita, D.
    Grivcheva-Panovska, V.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S29 - S29
  • [4] Assessment of HAE prophylaxis transition from androgen therapy to berotralstat: A subset analysis of the APeX-S trial
    Peter, Jonny G.
    Desai, Bhavisha
    Tomita, Dianne
    Collis, Phil
    Stobiecki, Marcin
    [J]. WORLD ALLERGY ORGANIZATION JOURNAL, 2023, 16 (11):
  • [5] Attack-free status across subgroups of patients with hereditary angioedema (HAE) after 96 weeks of berotralstat treatment: results from the APeX-S trial
    Reshef, A.
    Zafra, H.
    Johnston, D. T.
    Tomita, D.
    Desai, B.
    Aygoeren-Puersuen, E.
    [J]. ALLERGOLOGIE, 2023, 46 (08) : 558 - 558
  • [6] Berotralstat Consistently Demonstrates Reductions in Attack Frequency in Hereditary Angioedema (HAE) Irrespective of Baseline Attack Rate: Subgroup Analysis from the APeX2 Trial
    Li, H. Henry
    Best, Jessica
    Murray, Sharon
    Iocca, Heather
    Tachdijan, Raffi
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB22 - AB22
  • [7] BEROTRALSTAT DEMONSTRATES LOW HEREDITARY ANGIOEDEMA (HAE) ATTACK RATES IN PATIENTS S WITCHING FROM INJECTABLE PROPHYLAXIS
    Riedl, M.
    Sheridan, W.
    Noble, L.
    Tomita, D.
    Soteres, D.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S26 - S27
  • [8] Durable reduction in hereditary angioedema (HAE) attack rates with berotralstat over 24 months: results from the phase 3 apeX-2 study
    Kiani, S.
    Jacobs, J. S.
    Deasi, B.
    Aggarwal, K.
    Murray, S. C.
    Iocca, H.
    Lumry, W. R.
    [J]. ALLERGY, 2021, 76 : 16 - 16
  • [9] Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis
    Kokolakis, Georgios
    Vadstrup, Kasper
    Hansen, Jes B.
    Carrascosa, Jose Manuel
    [J]. DERMATOLOGY, 2022, 238 (04) : 620 - 629
  • [10] Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
    Thyssen, Jacob P.
    Bewley, Anthony
    Staender, Sonja
    Castro, Carla
    Misery, Laurent
    Kim, Brian S.
    Biswas, Pinaki
    Chan, Gary
    Myers, Daniela E.
    Watkins, Melissa
    Alderfer, Justine
    Gueler, Erman
    Silverberg, Jonathan I.
    [J]. DERMATOLOGY, 2024, 240 (02) : 255 - 265
12